Cinclus Pharma: Last patient visit completed in pivotal HEEALING1 study - Redeye

Redeye briefly comments on Cinclus Pharma's announcement that the last patient has completed the final safety follow-up visit (Last Patient Last Visit) in the phase III HEEALING1 study with lead candidate linaprazan glurate. All planned patient visits in the pivotal study are now complete. We view the update as the last operational step before the topline readout, which the company continues to expect in Q4 2026.

Länk till analysen i sin helhet: https://www.redeye.se/research/1186397/cinclus-pharma-last-patient-visit-completed-in-pivotal-heealing1-study?utm_source=finwire&utm_medium=RSS